Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042384 | 1.00 | DUSP3 (0.40) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL2795411 | 1.00 | DUSP3 (0.40) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL3048730 | 0.92 | PTPN5 (0.39) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL2795318 | 0.92 | PTPN5 (0.39) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL2793811 | 0.92 | PTPN5 (0.39) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL27504528 | 0.92 | AKR1B1 (0.40) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL27504531 | 0.89 | AKR1B1 (0.42) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL1998542 | 0.79 | PTGDR2 (0.47) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL3983073 | 0.77 | PTGDR2 (0.49) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 | |
| SCHEMBL4969723 | 0.77 | PTGDR2 (0.49) | DUSP3PTPN5PTPN11CTDSP1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | claimed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | claimed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | claimed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | disclosed |
| EP-2059505-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-05-20 | — | — | EP | disclosed |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008029349-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | disclosed |
| EP-1797040-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035303-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM5 | DUSP3 3924/4885PTPN5 3514/4885PTPN11 3303/4885 |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | DUSP3 3732/4885PTPN5 789/4885PTPN11 878/4885 |
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | DUSP3 4551/4885PTPN5 1765/4885PTPN11 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.